This finding was consistent with the potential of targeting Cpt1a or modulating FA metabolism alongside HER2-targeted therapy to enhance treatment efficacy in therapy-resistant HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.